Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study

Míreanna comhchosúla

• Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes: 5F9005 phase 1b study results
  de réir: Sallman, DA, et al.
  Foilsithe / Cruthaithe: (2022)
• MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
  de réir: Sallman, D, et al.
  Foilsithe / Cruthaithe: (2022)
• Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results
  de réir: Daver, NG, et al.
  Foilsithe / Cruthaithe: (2023)
• S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS
  de réir: D. A. Sallman, et al.
  Foilsithe / Cruthaithe: (2022-06-01)
• Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results
  de réir: Daver, NG, et al.
  Foilsithe / Cruthaithe: (2022)